Search Technologies

Showing 1-11 of 11 results found

Ratio Based Biomarkers for the Prediction of Cancer Survival

The NCI seeks licensees or co-development partners for this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.

Diagnostics

High-throughput Assay to Identify New Cancer Drugs

The National Cancer Institute seeks parties interested in collaborative research to evaluate or commercialize a diagnostic tool that can identify new drugs that increase chromosome instability.

Diagnostics
Research Tools

Argon to Improve Bioanalyte Stability in Fixed Tissue Specimens

The National Cancer Institute (NCI) seeks research licensees for a process that reduces nucleic acid (RNA and DNA) degradation and improves protein integrity in tissue preserved as fixed paraffin embedded specimens.

Diagnostics

Zirconium-89 PET Imaging Agent for Cancer

This technology is a new generation of rationally designed chelating agents that improve the complexation of Zirconium-89 for PET imaging of cancers.

Diagnostics
Research Tools

Method and Device for Selectively Labeling RNA

The National Cancer Institute's Structure Biophysics Lab seeks partners interested in licensing or co-developing a technology to site-specifically label RNA.

Diagnostics

Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters

Researchers at NCI developed twelve lentiviral vectors that express both fluorescent and luminescent markers as a single fusion protein under various gene promoters.

Diagnostics
Research Tools

Methods of Treating Diffuse Large B Cell Lymphoma Based on Particular Genetic Subtype (LymphGen) - A Genetic Classifier to Aid in the Molecular Diagnosis and Treatment of Diffuse Large B-cell Lymphoma

The National Cancer Institute (NCI) seeks research co-development or licensees for a precision medicine approach that classifies patients’ DLBCL into genetic subtypes that are predictive of treatment response.

Diagnostics

Silica-Coated Nanodiamonds for Imaging and Delivery of Therapeutic Agents

The NCI Radiation Oncology Branch and the NHLBI Laboratory of Single Molecule Biophysics seek parties to co-develop fluorescent nanodiamonds for use as in vivo and in vitro optical tracking probes toward commercialization.

Diagnostics

RNASEH-Assisted Detection Assay for RNA

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development and commercialization of a diagnostic assay that detects sequence-specific (viral) RNA.

Diagnostics

3D Image Rendering Software for Biological Tissues

The Frederick National Laboratory for Cancer Research seeks parties interested in collaborative research to co-develop software for the automatic 3-D visualization of biological image volumes.

Diagnostics
Software

High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources

The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a product or service for detecting and screening for endocrine disrupting chemicals (EDCs) in samples from water sources and/or wastewater.

Diagnostics

You are here

Product Type

Development Stage

Therapeutic Area

Institutes and Centers